Danaher Corporation (DHR) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.
Total Cash From Operating Activities Chart for Danaher Corporation
Danaher Corporation (DHR) operating cash flow for FY2025 was USD 6.4B, a -4.1% change from FY2024. Danaher Corporation's operating cash flow grew from USD 70.0M in 1990 to USD 6.4B in 2025 (9065.7% over 35 years). Operating cash flow compound annual growth rate: 5-year CAGR of 0.7%, 10-year CAGR of 5.4%, 20-year CAGR of 8.7%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $140.58B
- Implied Share Price
- $199.98
- Enterprise Value
- $159.28B
- Revenue (TTM)
- $25.11B
- EBITDA
- $8.03B
- Profit Margin
- 15.95%
- Trailing P/E
- 35.65
- Forward P/E
- 22.88
- Price/Book (MRQ)
- 2.61
- Price/Sales (TTM)
- 5.60
- EV/EBITDA
- 21.00
- EV/Revenue
- 6.34
- Dividend Yield
- 0.72%
- Book Value
- $74.81
- Free Cash Flow (FY2025)
- $5.26B
- Free Cash Flow Yield
- 3.74%
Snapshot as of 7th August 2026 — not point-in-time controlled, may lag the live market by a few days.